Profile data is unavailable for this security.
About the company
Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.
- Revenue in USD (TTM)65.18m
- Net income in USD-377.75m
- Incorporated2013
- Employees500.00
- LocationRecursion Pharmaceuticals Inc41S Rio Grande StreetSALT LAKE CITY 84101United StatesUSA
- Phone+1 (385) 269-0203
- Fax+1 (801) 581-7895
- Websitehttps://www.recursion.com/
More ▼
Mergers & acquisitions
| Acquired company | RXRX:NSQ since announced | Transaction value |
|---|---|---|
| Exscientia PLC | -9.18% | 427.00m |
Data delayed at least 15 minutes, as of Nov 22 2024 18:49 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cassava Sciences Inc | 0.00 | -17.66m | 1.54bn | 29.00 | -- | 9.26 | -- | -- | -0.3772 | -0.3772 | 0.00 | 3.47 | 0.00 | -- | -- | 0.00 | -8.91 | -30.74 | -10.98 | -32.12 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.50 | -- | -- | -- |
| Neumora Therapeutics Inc | 0.00 | -293.70m | 1.55bn | 108.00 | -- | 4.85 | -- | -- | -1.77 | -1.77 | 0.00 | 2.00 | 0.00 | -- | -- | 0.00 | -65.46 | -- | -70.23 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.23 | -- | -- | -- |
| BioCryst Pharmaceuticals Inc | 412.58m | -123.82m | 1.55bn | 536.00 | -- | -- | -- | 3.76 | -0.6073 | -0.6073 | 2.01 | -2.26 | 0.8136 | 0.4297 | 6.54 | 769,736.90 | -24.42 | -47.95 | -32.17 | -64.89 | 98.06 | 97.06 | -30.01 | -114.94 | 2.73 | -0.488 | 2.29 | -- | 22.37 | 74.21 | 8.33 | -- | 42.73 | -- |
| Viridian Therapeutics Inc | 302.00k | -257.08m | 1.55bn | 96.00 | -- | 3.00 | -- | 5,146.21 | -4.31 | -4.31 | 0.005 | 8.94 | 0.0006 | -- | 5.21 | 3,212.77 | -46.71 | -55.59 | -49.63 | -60.32 | -- | -- | -85,127.15 | -5,678.12 | -- | -- | 0.0282 | -- | -82.28 | -48.16 | -83.05 | -- | 15.08 | -- |
| Travere Therapeutics Inc | 203.45m | -348.96m | 1.57bn | 380.00 | -- | -- | -- | 7.69 | -4.52 | -4.56 | 2.63 | -0.3909 | 0.3043 | 0.7192 | 10.24 | 535,386.80 | -52.19 | -36.95 | -69.25 | -44.77 | 95.21 | 95.92 | -171.52 | -165.79 | 1.68 | -- | 1.09 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
| Nurix Therapeutics Inc | 56.42m | -176.98m | 1.58bn | 284.00 | -- | 3.98 | -- | 28.08 | -2.91 | -2.91 | 0.9222 | 5.62 | 0.1373 | -- | -- | 198,676.10 | -43.07 | -33.01 | -52.51 | -39.66 | -- | -- | -313.65 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
| Dynavax Technologies Corp | 260.81m | 20.48m | 1.62bn | 408.00 | 101.25 | 2.38 | 64.90 | 6.23 | 0.1221 | 0.1221 | 1.83 | 5.19 | 0.2563 | 0.80 | 4.36 | 639,242.60 | 2.01 | 4.16 | 2.14 | 5.71 | 82.85 | 64.83 | 7.85 | 9.19 | 12.34 | -- | 0.247 | 0.00 | -67.86 | 95.19 | -102.18 | -- | -23.03 | -- |
| Recursion Pharmaceuticals Inc | 65.18m | -377.75m | 1.65bn | 500.00 | -- | 3.13 | -- | 25.29 | -1.53 | -1.53 | 0.2631 | 1.83 | 0.096 | -- | 24.06 | 130,368.00 | -55.66 | -- | -65.45 | -- | 35.07 | -- | -579.51 | -- | -- | -- | 0.0519 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Xencor Inc | 85.16m | -198.24m | 1.69bn | 280.00 | -- | 2.33 | -- | 19.80 | -3.20 | -3.20 | 1.37 | 10.35 | 0.0967 | -- | 2.61 | 304,157.20 | -22.89 | -3.70 | -24.90 | -4.12 | -- | -- | -236.81 | -15.92 | -- | -- | 0.0243 | -- | 2.28 | 32.90 | -128.50 | -- | 18.36 | -- |
| Structure Therapeutics Inc (ADR) | 0.00 | -110.55m | 1.72bn | 148.00 | -- | 1.92 | -- | -- | -2.21 | -2.21 | 0.00 | 15.66 | 0.00 | -- | -- | 0.00 | -19.23 | -- | -20.17 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -69.62 | -- | -- | -- |
| Arvinas Inc | 161.10m | -308.60m | 1.73bn | 445.00 | -- | 2.94 | -- | 10.71 | -4.79 | -4.79 | 2.38 | 8.53 | 0.1448 | -- | 14.01 | 362,022.50 | -27.73 | -22.01 | -37.81 | -26.47 | -- | -- | -191.56 | -316.55 | -- | -- | 0.001 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Celldex Therapeutics, Inc. | 9.98m | -154.08m | 1.74bn | 160.00 | -- | 2.21 | -- | 174.37 | -2.57 | -2.57 | 0.164 | 11.85 | 0.0181 | -- | 18.07 | 62,350.00 | -27.93 | -29.65 | -29.53 | -31.42 | -- | -- | -1,544.48 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Fortrea Holdings Inc | 2.77bn | -233.60m | 1.75bn | 15.50k | -- | 1.16 | -- | 0.6297 | -2.62 | -3.40 | 31.09 | 16.87 | 0.6954 | -- | 3.20 | 154,155.60 | -5.85 | -- | -7.29 | -- | 18.49 | -- | -8.42 | -- | -- | -0.6141 | 0.4263 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
Data as of Nov 22 2024. Currency figures normalised to Recursion Pharmaceuticals Inc's reporting currency: US Dollar USD
57.67%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 30 Sep 2024 | 32.77m | 11.53% |
| Baillie Gifford & Co.as of 30 Sep 2024 | 25.24m | 8.88% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 23.61m | 8.31% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 17.75m | 6.25% |
| RA Capital Management LPas of 30 Sep 2024 | 15.38m | 5.41% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 12.87m | 4.53% |
| Nikko Asset Management Co., Ltd.as of 30 Sep 2024 | 9.77m | 3.44% |
| Nikko Asset Management Americas, Inc.as of 30 Sep 2024 | 9.69m | 3.41% |
| MIC Capital Management UK LLPas of 30 Sep 2024 | 8.45m | 2.97% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 8.34m | 2.93% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
